Telehealth firm 9amHealth has partnered with Mark Cuban’s Cost Plus Drug Company to provide U.S. employers with lower-cost obesity treatment options. The collaboration aims to expand access to affordable medications for weight management and chronic conditions such as diabetes, high cholesterol, and hypertension.
How Cost Plus Drugs Lowers Prices
Cost Plus Drugs contracts directly with manufacturers, applying a standard markup to ensure transparent pricing. The company has also partnered with pharmacy benefit managers RxPreferred and AffirmedRx to offer lower-priced medications through some employer-backed health insurance plans.
Medications Available Through the Partnership
- Generic GLP-1 diabetes drug Victoza (Novo Nordisk) in injectable form.
- Branded GLP-1 obesity medications through direct manufacturer partnerships.
- Other generic drugs, including topiramate, metformin, bupropion, and naltrexone.
Addressing High Costs of Weight-Loss Drugs
Newer weight-loss medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, can cost up to $1,000 per month without insurance coverage. The partnership aims to reduce financial barriers for employers and employees seeking effective obesity treatments.
Industry Impact and Future Outlook
Mark Cuban’s Cost Plus Drug Company continues to disrupt the pharmaceutical industry by offering transparent pricing and direct-to-consumer drug access. The partnership with 9amHealth aligns with broader efforts to expand affordable healthcare solutions.
For more details, visit SRN News.
